Source: http://www.google.com/patents/US7704505?dq=7,094,863
Timestamp: 2014-11-21 03:16:25
Document Index: 132490703

Matched Legal Cases: ['Application No. 06003224', 'Application No. 2006', 'Application No. 2006', 'Application No. 2006', 'Application No. 2006', 'Application No. 2006', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007', 'Application No. 2008', 'Application No. 2008', 'Application No. 8', 'Application No. 8', 'Application No. 8', 'Application No. 8', 'ART 2', 'ART 2']

Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4659563Jan 27, 1986Apr 21, 1987Miles Laboratories, Inc.High titer anti-respiratory syncytial virus intravenous immune globulinUS4717766Mar 9, 1987Jan 5, 1988Miles Laboratories, Inc.Screening donor plasma; fractionationUS4800078May 28, 1987Jan 24, 1989The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesImmunoglobulinsUS5071758Jan 27, 1989Dec 10, 1991National Research Development CorporationVeterinary medicineUS5183657Mar 13, 1989Feb 2, 1993Celltech LimitedAntibodies for use in antilymphocyte antibody therapyUS5194595Oct 31, 1988Mar 16, 1993The Upjohn CompanyChimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virusUS5219996Sep 5, 1988Jun 15, 1993Celltech LimitedRecombinant antibodies and methods for their production in which surface residues are altered to cysteine residues for attachment of effector or receptor moleculesUS5223254Sep 20, 1988Jun 29, 1993Praxis Biologics, Inc.PolypeptideUS5225539Oct 25, 1991Jul 6, 1993Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodiesUS5240694Nov 19, 1991Aug 31, 1993University Of VirginiaCombined antiviral and antimediator treatment of common coldsUS5288630Nov 20, 1992Feb 22, 1994The Upjohn CompanyFor preparing specific immune responses against human respiratory syncytial virusUS5290540May 1, 1992Mar 1, 1994Henry M. Jackson Foundation For The Advancement Of Military MedicineAdministering, in small particle aerosol form, an anti-inflammatory agent of a corticosteroid, indomethacin, ibuprofen or acetylsalicylic acid and an anti-infectious agentUS5332567Mar 22, 1993Jul 26, 1994ImmunomedicsDetection and treatment of infections with immunoconjugatesUS5693762Jun 7, 1995Dec 2, 1997Protein Design Labs, Inc.Humanized immunoglobulinsUS5824307 *Aug 15, 1994Oct 20, 1998Medimmune, Inc.Human-murine chimeric antibodies against respiratory syncytial virusAU713113B2 Title not availableCA2197684A1Aug 9, 1995Feb 22, 1996Medimmune IncHuman-murine chimeric antibodies against respiratory syncytial virusEP0327378A1Feb 3, 1989Aug 9, 1989The Trustees Of Columbia University In The City Of New YorkDomain-modified constant region antibodiesEP0368684A1Nov 13, 1989May 16, 1990Medical Research CouncilCloning immunoglobulin variable domain sequences.EP0671927A1Sep 16, 1993Sep 20, 1995The Scripps Research InstituteHuman neutralizing monoclonal antibodies to respiratory syncytial virusWO1990007861A1Dec 28, 1989Jul 26, 1990Protein Design Labs IncCHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTORWO1992004381A1Sep 11, 1991Mar 12, 1992Scotgen LtdNovel antibodies for treatment and prevention of infection in animals and manWO1992005274A1Sep 16, 1991Apr 2, 1992Michael Ronald ClarkFramework mutated antibodies and their preparationWO1992019244A2May 1, 1992Nov 12, 1992Jackson H M Found Military MedA method for treating infectious respiratory diseasesWO1993005796A1Sep 18, 1992Apr 1, 1993Scripps Research InstMethod for producing human antibodies in a non-human animal, and animals thereforWO1993015199A1Jan 28, 1993Aug 5, 1993Rhone Poulenc Rorer SaNovel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptidesWO1993015200A1Jan 28, 1993Aug 5, 1993Rhone Poulenc Rorer SaAntithrombotic polypeptides as antagonists of the binding of vwf to platelets or to subendotheliumWO1993019197A1Mar 18, 1993Sep 30, 1993ImmunetHuman monoclonal antibodies and methods for human monoclonal antibody productionWO1993020210A1Apr 6, 1993Oct 14, 1993Scotgen LtdAntibodies for treatment and prevention of respiratory syncytial virus infectionWO1994006448A1Sep 16, 1993Mar 31, 1994Carlos F Barbas IiiHuman neutralizing monoclonal antibodies to respiratory syncytial virusWO1994017105A1Jan 29, 1993Aug 4, 1994Medimmune IncHuman-murine chimeric antibodies against respiratory syncytial virusWO1994029351A2Jun 15, 1994Dec 22, 1994Diljeet Singh AthwalAntibodies* Cited by examinerNon-Patent CitationsReference1Ames et al., 1995. Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. J. Immunol Methods.184(2):177-86.2Arbiza et al., 1992 "Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus," J. Gen. Virol. 73: 2225-2234.3Balint and Larrick, 1993, "Antibody engineering by parsimonious mutagenesis." Gene. 137(1):109-118.4Beeler et al., 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function", J Virol. 63(7):2941-50.5Beeler, et al.; 1989, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation upon Fusion Function", Journal of Virology, 63(7):2941-2950.6Better et al., 1988. Escherichia coli secretion of an active chimeric antibody fragment. Science. 240(4855):1041-3.7Boulianne et al., 1984, "Production of functional chimaeric mouse/human antibody," Nature 312 (1995):643-646.8Burton and Barbas, 1994. Human antibodies from combinatorial libraries. Adv. Immunol. 57:191-280.9Carson and Freimark, 1986, "Human lymphocyte hybridomas and monoclonal antibodies," Adv. Immunol. 38:275-311.10Colman, 1994. Effects of amino acid sequence changes on antibody-antigen interactions; Res Immunol. 145(1):33-6.11EP Application Serial No. 95 928 353 (EP Patent No. 0783525)-Communication pursuant to Article 96(2) EPC dated Feb 28, 2002.12EP Application Serial No. 95 928 353 (EP Patent No. 0783525)�Communication pursuant to Article 96(2) EPC dated Feb 28, 2002.13EP Application Serial No. 95 928 353 (EP Patent No. 0783525)-Communication pursuant to Article 96(2) EPC dated Mar. 6, 2003.14EP Application Serial No. 95 928 353 (EP Patent No. 0783525)�Communication pursuant to Article 96(2) EPC dated Mar. 6, 2003.15EP Application Serial No. 95 928 353 (EP Patent No. 0783525)-Communication under Rule 51(4) EPC Intention to Grant dated Feb. 20, 2006.16EP Application Serial No. 95 928 353 (EP Patent No. 0783525)�Communication under Rule 51(4) EPC Intention to Grant dated Feb. 20, 2006.17EP Application Serial No. 95 928 353 (EP Patent No. 0783525)-Invitation pursuant to Article 96(2) & Rule 52(2) EPC dated Mar. 31, 2004.18EP Application Serial No. 95 928 353 (EP Patent No. 0783525)�Invitation pursuant to Article 96(2) & Rule 52(2) EPC dated Mar. 31, 2004.19EP Application Serial No. 95 928 353 (EP Patent No. 0783525)-Summons to Attend Oral Proceedings under Rule 71(1) EPC dated Jul. 27, 2005.20EP Application Serial No. 95 928 353 (EP Patent No. 0783525)�Summons to Attend Oral Proceedings under Rule 71(1) EPC dated Jul. 27, 2005.21European Search Report corresponding to EP Application No. 06003224.0 dated Dec. 19, 2008.22Foote et al., "Kinetic maturation of an immune response," Nature, vol. 352:530-532 (Aug. 8, 1991).23Garcia-Barreno. et al.1989 , "Marked Differences in the Antigenic Structure of Human Respiratory Syncytial Virus F and G Glycoproteins," J Virol. 63(2):925-32.24Gillies et al., 1989. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol Methods. 125:191-202.25Glaser et al., 1992, "Antibody engineering by codon-based mutagenesis in a filamentous phage vector system," J. Immunol. 149: 3903-3913.26Groothius et al., 1993, "Prophylactic Administration of Respiratory syncytial Virus Immune Globulin to High-Risk Infants and Young Children," The Respiratory Syncytial Virus Immune Globulin Study Group, N Engl J Med. 329(21):1524-1530.27Groothuis et al., 1988, "Respiratory Syncytial Virus Infection in children with Bronchopulmonary Dysplasia," Pediatrics. 82(2):199-203.28Hellstrom et al., 1987. Antibodies for drug delivery. Controlled Drug Delivery, Fundamentals and Applications 2nd edition. Chapter 15: p. 623-653.29Hemming et al., "Immunoglobulins in respiratory syncytial virus infections," Clinical Use of Intravenous Immunoglobulins, Morell and Nydegger., eds., Academic Press, London, pp. 285-294 (1986).30Hemming et al., 1985, "Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model," J Infect Dis. 152(5):1083-1087.31Johnson et al., 1987, "The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins", Proc Natl Acad Sci U S A. 84(16):5625-9.32Johnson et al., 1991. Development of humanized monoclonal antibodies which neutralize respiratory syncytial virus. J. Cellular Biochem. Suppl. 15E. p. 120. Abstract No. 108.33Johnson, et al.; 1997, "Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus", The Journal of Infectious Diseases, 176:1215-1224.34Johnson, et al.; 1999, "A Direct Comparison of the Activities of Two Humanized Respiratory Syncytial Virus Monoclonal Antibodies: MEDI-493 and RSHZ19", The Journal of Infectious Diseases, 180:35-40.35Johnson, Leslie S., "Human-Murine Chimeric Abs to Respiratory Syncytial Virus," NIAID Grant No. 5R44AI030300-02 Abstract (1993) http://crisp.cit.nih.gov/crisp/CRISP-LIB.getdoc?textkey=2065544&p-grant-num=2R44AI030300-02&p.36Johnson, Leslie S., "Human-Murine Chimeric Abs to Respiratory Syncytial Virus," NIAID Grant No. 5R44AI030300-03 Abstract (1994) http://crisp.cit.nih.gov/crisp/CRISP-LIB.getdoc?textkey=2065544&p-grant-num=2R44AI030300-02&p.37Johnson, Leslie S., "Human-Murine Chimeric Abs to Respiratory Syncytial Virus," NIAID Grant No. 5R44AI030300-02 Abstract (1993) http://crisp.cit.nih.gov/crisp/CRISP�LIB.getdoc?textkey=2065544&p�grant�num=2R44AI030300-02&p.38Johnson, Leslie S., "Human-Murine Chimeric Abs to Respiratory Syncytial Virus," NIAID Grant No. 5R44AI030300-03 Abstract (1994) http://crisp.cit.nih.gov/crisp/CRISP�LIB.getdoc?textkey=2065544&p�grant�num=2R44AI030300-02&p.39Jones, et al.; 1986, "Replacing the complementarity-determining regions in a human antibody with those from a mouse", Nature, 321:522-525.40JP Application No. 2006-152600 (JP Patent No. JP 4216297)�Translation of Decision of Rejection dated Mar. 29, 2007.41JP Application No. 2006-152600 (JP Patent No. JP 4216297)�Translation of Notification of Reasons for Rejection dated May 13, 2008.42JP Application No. 2006-152600 (JP Patent No. JP 4216297)�Translation of Notification of Reasons for Rejection dated Sep. 5, 2006.43JP Application No. 2006-152600 (JP Patent No. JP 4216297)�Translation of Report of the Reconsideration by Examiner dated Sep. 28, 2007.44JP Application No. 2006-152600 (JP Patent No. JP 4216297)�Translation of Trial Decision Reversing all Grounds of Rejection dated Oct. 7, 2008.45JP Application No. 2007-200866�Translation of Decision of Rejection dated May 7, 2008.46JP Application No. 2007-200866�Translation of Notification of Reasons for Rejection dated Oct. 2, 2007.47JP Application No. 2007-200866�Translation of Report of the Reconsideration by Examiner (Modified) dated Jan. 7, 2009.48JP Application No. 2007-200866�Translation of Report of the Reconsideration by Examiner dated Jan. 7, 2009.49JP Application No. 2007-200866�Translation of Written Withdrawal dated Apr. 28, 2009.50JP Application No. 2008-227316�Translation of Notification of Reasons for Rejection dated Dec. 9, 2008.51JP Application No. 2008-227316�Translation of Notification of Reasons for Rejection Final dated Jul. 7, 2009.52JP Application No. 8-507450 (JP Patent No. JP 3896160)�Translation of Final Rejection dated Jan. 31, 2006.53JP Application No. 8-507450 (JP Patent No. JP 3896160)�Translation of Notice of Reason of Refusal dated Mar. 1, 2005.54JP Application No. 8-507450 (JP Patent No. JP 3896160)�Translation of Report of the Reconsideration by Examiner dated Aug. 28, 2008.55JP Application No. 8-507450 (JP Patent No. JP 3896160)�Translation of Trial Decision Reversing all Grounds of Rejection dated Dec. 13, 2006.56Kudo et al., 1992. New strategies to establish human monoclonal antibodies; Tohoku J Exp Med. 168(2):323-327.57Kudo et al., 1993. Production of a human monoclonal antibody to a synthetic peptide by active in vivo immunization using a SCID mouse grafted with human lymphocytes; Tohoku J Exp Med. 171: 327-338.58Landry et al., "Evaluation of Reconstituted Lyophilized Palivizumab (Synagis(TM)) Given Intravenously at 15 and 30 mg/kg," Annual Meeting of the American Pediatric Society and the Society for Pediatric Research, Meeting Poster/Abstract 969, Pediatric Research 45(4 PART 2):166A (1999).59Landry et al., "Evaluation of Reconstituted Lyophilized Palivizumab (Synagis�) Given Intravenously at 15 and 30 mg/kg," Annual Meeting of the American Pediatric Society and the Society for Pediatric Research, Meeting Poster/Abstract 969, Pediatric Research 45(4 PART 2):166A (1999).60Langer, 1990. New methods of drug delivery. Science. 249:1527-1533.61Lee F. et al., 1992. Calculations of Antibody-Antigen Interactions: Microscopic and semi-microscopic evaluation of the free energies of binding of phophorylcholine analogs to McPc603, Protein Engineering vol. 5 No. 3 pp. 215-222.62Liu, et al., 1987, "Expression of mouse:human immunoglobulin heavy-chain cDNA in lymphoid cells," Gene 54(1):33-40.63LoBuglio et al., 1989, "Mouse/human chimeric monoclonal antibody in man: kinetics and immune response," Proc.Natl.Acad.Scie. USA 86(11):4220-4224.64Marks et al., 1992, "By-passing immunization: building high affinity human antibodies by chain shuffling," Biotechnology (NY) 10(7):779-83.65MedImmune, Inc, 1999 SYNAGIS (registered trademark) package insert, revised Dec. 2, 1999.66Medlmmune, SYNAGIS (registered trademark) package insert, last revised Oct. 23, 2002.67Meissner, et al.; 1999, "Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease", Antimicrobial Agents and Chemotherapy, 43(5):1183-1188.68Morell et al., eds, 1986, Clinical Use of Intravenous Immunoglobulins, Academic Press, London, pp. 285-294.69Morrision et al., 1984, "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," PNAS USA 81(21):6851-6855.70Morrision et al., 1985, "Transfectomas provide novel chimeric antibodies," Science 229(4719):1202-1207.71Mullinax et al., 1992. Expression of a heterodimeric Fab antibody protein in one cloning step. Bio Techniques. 12:864-869.72Murphy et al., 1988, "Passive Transfer of Respiratory syncytial Virus (RSV) Antiserum Suppresses The Immune Response to the RSV Fusion (F) and Lage (G) Glycoproteins Expressed by Recombinant Vaccinia Viruses," J Virol. 62(10):3907-3910.73Murphy et al., 1991, "Effect of Passive Antibody on the Immune Response of Cotton Rats to Purified F and G HG Glycoproteins of Respiratory Syncytial Virus (RSV)," Vaccine. 9(3):185-189.74Newman et al., "Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4," vol. 10, pp. 1455-1460, Nov. 1992.75Padlan, 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28(4/5):489-498.76Palomo et al., 1990 "Induction of a Neutralizing Immune Response to Human Respiratory Syncytial Virus with Anti-Idiotypic Antibodies," J. Virology 64(9): 4199-4206.77Prince et al., 1983, "Mechanisms of Immunity to Respiratory Syncytial Virus in Cotton Rats," Infect Immun. 42(1):81-87.78Prince et al., 1985, "Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus Infection in the Cotton Rat," Virus Res.3(3):193-206.79Prince, et al.; 1985, "Quantitative Aspects of Passive Immunity to Respiratory Syncytial Virus Infection in Infant Cotton Rats", Journal of Virology, 55(3):517-520.80Riechmann et al., 1988. Reshaping human antibodies for therapy. Nature. 332(6162):323-7.81Roguska et al., 1994, "Humanization of murine monoclonal antibodies through variable domain resurfacing," Proc. Natl. Acad. Sci. U.S.A. 91(3):969-973.82Roitt, 1991, "The Recognition of of Antigen 1-Primary Interaction", Essential Immunology, 4:65-83.83Roitt, 1991, "The Recognition of of Antigen 1�Primary Interaction", Essential Immunology, 4:65-83.84Rudikoff et al., 1982, "Single amino acid substitution altering antigen-binding specificity," PNAS USA 79(6):1979-1983.85Sahagan et al., 1986, "A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen," J.Immunol. 137(3):1066-1074.86Seaver, 1994. Monoclonal antibodies in industry: More difficult than originally thought; Genetic Engineering News, vol. 14, No. 14, p. 10 and 21.87Sevier et al., 1981. Monoclonal antibodies in clinical immunology. Clin Chem. 27(11):1797-806.88Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976.89Sorbera et al., 1998, "Palivizumab," Drums Data Report 20:702-703.90Steplewski et al., 1988, "Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity," PNAS USA 85(13):4852-4856.91Stott, et al.; 1984, "Characterization and Uses of Monoclonal Antibodies To Respiratory Syncytial Virus", Developmental and Biological Standarization, 57:237-244.92Studnicka et al., 1994. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulatin: residues. Protein Eng. 7:805-814.93Sun et al., 1987, "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A," PNAS USA 84(1):214-218.94Takahashi et al. 1984. Rearranged immunoglobulin heavy chain variable region (VH) pseudogene that deletes the second complementarity-determining region. PNAS 81: 5194-198.95Takeda et al., 1985, "Construction of chimeaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," Nature 314(6010):4520454.96Talwar et al., PNAS 1976 73(1):218-222.97Taylor et al., 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 52(1):137-42.98Taylor et al., 1992. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. J Gen Virol. 73 ( Pt 9):2217-23.99Tempest, et al.; 1991, "Reshaping a Human Monoclonal Antibody To Inhibit Human Respiratory Syncytial Virus Infection In Vivo", Biotechnology, 9:266-271.100The Impact-RSV Study Group, 1998, "Palivizumab ,A Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants,". Pediatrics. 102(3 Pt 1):531-537.101U.S. Appl. No. 07/813,372, filed Dec. 23, 1991, Leslie S. Johnson.102U.S. Appl. No. 08/290,592-Final Rejection dated Jul. 21, 2007.103U.S. Appl. No. 08/290,592�Final Rejection dated Jul. 21, 2007.104U.S. Appl. No. 08/290,592-Interview summary dated Apr. 13, 1998.105U.S. Appl. No. 08/290,592�Interview summary dated Apr. 13, 1998.106U.S. Appl. No. 08/290,592-Interview summary dated Feb. 4, 1998.107U.S. Appl. No. 08/290,592�Interview summary dated Feb. 4, 1998.108U.S. Appl. No. 08/290,592-Interview summary dated Jan. 23, 1998.109U.S. Appl. No. 08/290,592�Interview summary dated Jan. 23, 1998.110U.S. Appl. No. 08/290,592-Notice of Allowability & Examiners Amdt dated Apr. 30, 1998.111U.S. Appl. No. 08/290,592�Notice of Allowability & Examiners Amdt dated Apr. 30, 1998.112U.S. Appl. No. 08/290,592-Restrction and Non-Final Rejection dated Nov. 24, 1995.113U.S. Appl. No. 08/290,592�Restrction and Non-Final Rejection dated Nov. 24, 1995.114U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Final Rejection dated Feb. 9, 2005.115U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Final Rejection dated Feb. 9, 2005.116U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Final Rejection dated Jan. 13, 2003.117U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Final Rejection dated Jan. 13, 2003.118U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Final Rejection dated Jan. 16, 2001.119U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Final Rejection dated Jan. 16, 2001.120U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Non-Final Rejection dated Apr. 20, 2004.121U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Non-Final Rejection dated Apr. 20, 2004.122U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Non-Final Rejection dated Apr. 26, 2000.123U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Non-Final Rejection dated Apr. 26, 2000.124U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Non-Final Rejection dated Mar. 6, 2002.125U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Non-Final Rejection dated Mar. 6, 2002.126U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)-Notice of Abandonment dated Aug. 23, 2005.127U.S. Appl. No. 09/158,120 (U.S. Publ. No. 2002-0102257)�Notice of Abandonment dated Aug. 23, 2005.128U.S. Appl. No. 09/158,120, filed Sep. 21, 1998, Johnson.129U.S. Appl. No. 11/198,322 (U.S. Publ. No. 2007-0020279)-Non Final Rejection dated May 6, 2008.130U.S. Appl. No. 11/198,322 (U.S. Publ. No. 2007-0020279)�Non Final Rejection dated May 6, 2008.131U.S. Appl. No. 11/198,322 (U.S. Publ. No. 2007-0020279)-Notice of Abandonment dated Dec. 8, 2008.132U.S. Appl. No. 11/198,322 (U.S. Publ. No. 2007-0020279)�Notice of Abandonment dated Dec. 8, 2008.133U.S. Appl. No. 11/198,322, filed Aug. 8, 2005, Johnson.134Walsh et al., 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 43(2):756-8.135Walsh et al., 1987, "Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection", J Infect Dis. 155(6):1198-204.136Walsh, et al.; 1989, "Comparison of Antigenic Sites of Subtype-specific Respiratory Syncytial Virus Attachment Proteins," Journal of General Virology, 70:2953-2961.137Ware et al., 1985. Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID). J Immunol Methods. 85(2):353-61.138Weltzin et al., 1994, "Intranasal Monoclonal Immunoglobulin A against Respiratory Syncytial Virus Protects against Upper and Lower Respiratory Tract Infections in Mice." Antimicro Agents & Chemo. 38(12):2785-2791.139Winter G. et al , Humanized Antibodies, Immunology Today vol. 14 No. 6 1993 pp. 243-246.Classifications U.S. Classification424/147.1, 424/141.1, 424/130.1International ClassificationC12P21/08, C07K16/08, A61K39/395, A61K39/42, A61K38/00, C07K14/46, C07K16/10, A61P31/12, C12N15/09, C07K14/08Cooperative ClassificationC07K2317/24, A61K38/00, C07K2317/30, C07K2317/76, C07K2319/00, C07K16/1027, A61K2039/505, C07K2317/92European ClassificationC07K16/10FLegal EventsDateCodeEventDescriptionOct 28, 2013FPAYFee paymentYear of fee payment: 4Apr 30, 2009ASAssignmentOwner name: MEDIMMUNE, LLC, MARYLANDFree format text: CHANGE OF NAME;ASSIGNOR:MEDIMMUNE, INC.;REEL/FRAME:022617/0793Effective date: 20080325Owner name: MEDIMMUNE, LLC,MARYLANDFree format text: CHANGE OF NAME;ASSIGNOR:MEDIMMUNE, INC.;US-ASSIGNMENT DATABASE UPDATED:20100427;REEL/FRAME:22617/793RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google